sglt2 and glp 1 SGLT2i GLP-1 RA therapy in type diabetes and reno-vascular outcomes: a real-world study | Diabetologia Study participants' HbA1c: effect of

For example, LY3437943 , a novel triple agonist peptide discovered by Eli Lilly that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and GLP-1R (GCGR+GIPR+GLP-1R from the list above), can effectively reduce body weight and improve glycemic control in obese mice

Heres how this oral medication compares to the current GLP-1 treatments approved for weight loss: What will orforglipron cost

Ducker, G

Such findings could pave the way for more holistic approaches to treating type 2 diabetes, emphasizing the interconnectedness of weight management and glycemic control